COP vs JNJ: Which Is the Better Buy?
Side-by-side comparison of ConocoPhillips and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
ConocoPhillips · Energy
$125.78
-2.1% upside to fair value
Grade C
VS
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
QuantHub Verdict
JNJ has more upside to fair value
(+10.8%).
COP trades at a lower forward P/E
(21.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
COP |
JNJ |
| Current Price |
$125.78 |
$230.69 |
| Fair Value Estimate |
$123.15 |
$255.61 |
| Upside to Fair Value |
-2.1%
|
+10.8%
|
| Market Cap |
$153.3B |
$555.9B |
| Forward P/E |
21.0x
|
26.8x
|
| EV / EBITDA |
7.5x
|
18.5x
|
| Price / Sales |
2.6x
|
5.8x
|
| Price / FCF |
8.4x
|
28.2x
|
| Revenue Growth YoY |
-2.5%
|
+9.9%
|
| Gross Margin |
33.1%
|
69.1%
|
| Operating Margin |
25.4%
|
26.9%
|
| Return on Equity |
11.3%
|
26.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
11.96%
|
3.54%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
ConocoPhillips is a leading independent oil and gas exploration and production company with a strong focus on low-cost shale assets and sustainability initiatives. The company benefits from a durable competitive position due to its cost advantage and early ESG leadership, but faces near-term earnings pressure as revenue declined 2.5% and earnings fell 23.4% in the most recent quarter year-over-ye…
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Accumulation Zones
| Metric |
COP |
JNJ |
| Zone Low |
$92.36 |
$191.71 |
| Zone High |
$104.68 |
$217.27 |
| In Buy Zone? |
No
|
No
|